Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice

A Kuzmin1, J Sandin, L Terenius

  • 1Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Alexander.Kuzmin@fyfa.ki.se

Insights

Kappa-opioid agonists show dual effects on mouse motor activity. Low doses stimulate, while high doses suppress activity, indicating interaction with distinct opioid receptor subtypes.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Behavioral Science

Background:

  • Opioid receptors, specifically kappa-opioid receptors, are known to modulate motor activity and pain.
  • Previous research suggests complex interactions between opioid agonists and motor function, but the precise mechanisms and receptor subtypes involved require further elucidation.

Purpose of the Study:

  • To compare the effects of kappa-opioid agonists (U50488H, bremazocine, BRL52537) and a mu-opioid agonist (morphine) on spontaneous motor activity in mice.
  • To investigate the receptor subtypes and mechanisms underlying the observed motor effects of these opioid agonists.

Main Methods:

  • Administration of various kappa- and mu-opioid agonists and their selective antagonists to male NMRI mice.
  • Assessment of spontaneous motor activity, including rearing, motility, and locomotion, in both habituated and nonhabituated animals.
  • Dopamine depletion and blockade of opioid receptors using specific antagonists (nor-binaltorphimine, DIPPA, naloxone, beta-funaltrexamine) to elucidate mechanisms.

Main Results:

  • Higher doses of kappa-opioid agonists reduced motor activity and produced analgesia, blocked by kappa-opioid antagonists.
  • Lower doses of kappa-opioid agonists dose-dependently increased motor activity, an effect sensitive to naloxone but not kappa-antagonists, and dependent on dopamine activity and habituation.
  • Morphine's effects were dose-dependent, with initial suppression followed by stimulation, mediated by mu-opioid receptors.

Conclusions:

  • Kappa-opioid agonists interact with at least two functional opioid receptor subtypes: a classic inhibitory receptor mediating analgesia and motor suppression at high doses, and a stimulatory, naloxone-sensitive receptor involved in motor activation under specific conditions.
  • The stimulatory kappa-opioid effects are distinct from mu-opioid receptor-mediated effects and appear to involve a novel opioid receptor subtype that interacts with the dopaminergic system.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect01:28

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...